symp1

0

M. Belvisi (U.K.): Transduction mechanisms in airway inflammation.

P. Geppeti (Italy): Proteinase-activated receptor-2 and airways.

V. Lagente (France): Selective phosphodiesterase inhibitors as new anti-inflammatory compounds for the treatment of airway diseases.

F.P. Nijkamp (The Netherlands): Neuro-immune interactions in the lung and the role of tachykinins and nerve growth factor.

D. Hay (U.S.A.): Therapeutic opportunities and challenges for NK-3 receptor antagonists.

N. Frossard (France): Increased production of NGF by IL-1b and bronchial hyperresponsiveness.